Background: One year of trastuzumab, chosen empirically, improves survival of women with early-stage, HER2-positive breast cancer but also adds substantially to cost, toxicity, and inconvenience. Longer treatment does not improve outcomes, but potentiates toxicities.
New data presented at the San Antonio Breast Cancer Symposium today has been shown that trastuzumab is not a beneficial treatment for patients with breast cancer already undergoing chemotherapy.
Objective: To review the chemistry, pharmacology, pharmacokinetics, safety, and efficacy of neratinib in human epidermal growth factor receptor (HER2)+ breast cancer (BC).
Puma Biotechnology announced that the FDA has approved Nerlynx (neratinib), formerly known as PB272, a once-daily oral tyrosine kinase inhibitor...
Background: Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable.
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.
We evaluated the effect of Tz in combination with RA on the viability, adhesion, migration, invasion and expression of migration-related proteins in SKBR3 and BT-474 human breast cancer cells.
Objective: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which accounts for 20 – 25% of cases of breast cancers, is highly aggressive. Due to cardiotoxicity and increasing resistance associated with...
Puma Biotechnology, Inc. has announced that the Marketing Authorization Application (MAA) for neratinib has been validated by the European Medicines...
Nine weeks of trastuzumab may be sufficient for patients who receive higher dose of docetaxel.